DelveInsight’s “Acute Ocular Pain Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the acute ocular pain treatment market, historical and forecasted epidemiology, as well as market trends across the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report comprehensively evaluates the current treatment landscape, emerging therapies, market share of individual treatments, and acute ocular pain market forecasts through 2034, providing crucial insights for stakeholders in the acute ocular pain therapeutic area.
According to DelveInsight’s analysis, the acute ocular pain treatment market is projected to grow substantially during the forecast period (2025-2034), driven by enhanced understanding of disease mechanisms, technological advancements in acute ocular pain diagnostic techniques, and increasing awareness among healthcare providers and patients.
The report reveals that in 2023, the total acute ocular pain market size was approximately USD 260 million in the US. Furthermore, among the EU4 and the UK, Germany holds the largest market size of around USD 19 million, followed by France and Italy with approximately USD 16 million and USD 15 million, respectively. These market numbers are expected to change significantly during the forecast period (2024-2034), driven by ongoing research and development efforts that may lead to the discovery of more effective medications and therapies.
Download the Acute Ocular Pain market report to understand which factors are driving the Acute Ocular Pain therapeutic market @ Acute Ocular Pain Market Trends.
According to DelveInsight’s estimates, the US accounted for nearly 4 million acute ocular pain cases in 2023, which is anticipated to rise during the forecasted period primarily due to increased awareness and the higher prevalence of age-related eye conditions like cataracts, macular degeneration, and glaucoma. Among the EU4 and the UK, Germany had the highest number of cases, followed by France and Italy. Japan accounted for nearly 870 thousand cases of acute ocular pain in major eye disorders in 2023, with cases expected to increase by 2034 due to the growing prevalence of an aging population.
The DelveInsight report further categorizes the acute ocular pain patient population into several groups for analysis, including cases arising from cataract surgeries, corneal aberration surgery, uveitis, dry eye disease, glaucoma surgeries, and conjunctivitis. This classification is essential for understanding the distribution, progression, and treatment responses of different acute ocular pain etiologies and is crucial for accurate epidemiological assessment.
Discover evolving trends in the Acute Ocular Pain patient pool forecasts @ Acute Ocular Pain Epidemiology Analysis.
The report also discusses the current and emerging acute ocular pain treatment landscape. The current treatment landscape features several FDA-approved acute ocular pain therapies that have revolutionized patient care. DEXTENZA stands out as the pioneering FDA-approved intracanalicular insert, offering a novel administration route that bypasses the need for frequent topical applications. INVELTYS, combining loteprednol etabonate and KPI-121 in a nanoparticle corticosteroid formulation, targets postoperative ocular inflammation and pain effectively. BROMSITE, utilizing a polymer-based formulation, enhances solubility, absorption, bioavailability, and duration of action compared to traditional topical treatments. Other approved therapies include OMIDRIA, NEVANAC, PROLENSA, and LOTEMAX, all contributing to comprehensive acute ocular pain management.
According to the DelveInsight report, the acute ocular pain therapies pipeline is robust and promising, with several novel treatments in development. OCS-01 by Oculis SA represents a novel formulation of dexamethasone using proprietary Solubilizing Nanoparticle (SNP) technology, currently in Phase III development in the US for evaluating efficacy and safety following cataract surgery. APP13007 by Formosa Pharmaceuticals has reported successful top-line results from pivotal Phase III clinical studies, with licensing agreements established with Eyenovia for the US, and China Grand Pharmaceutical for China, Hong Kong, and Macau. Additional promising acute ocular pain pipeline candidates include SURF (Surface Ophthalmics), SVT-15473 (Salvat Laboratories), SDN-037 (Visiox Pharma), and DEXYCU (EyePoint Pharmaceuticals).
Recent developments in the acute ocular pain treatment landscape continue to show promise for addressing unmet medical needs. Clinical data indicate that specific patient populations experience varying rates of postoperative pain, with approximately 20% of patients suffering from pain after glaucoma surgery and 1-2% experiencing postoperative acute ocular pain following cataract surgeries.
Discover recent advancements in the Acute Ocular Pain treatment landscape @ Acute Ocular Pain Recent Developments.
According to DelveInsight’s report, the acute ocular pain treatment market is highly competitive, with major players including Ocular Therapeutix, Kala Pharmaceuticals, Sun Pharmaceutical, Bausch & Lomb, Omeros Corporation, Oculis SA, Formosa Pharmaceuticals, Surface Ophthalmics, Salvat Laboratories, Visiox Pharma, and EyePoint Pharmaceuticals, all advancing a variety of therapies through robust research and development initiatives and strategic collaborations.
Looking ahead, the acute ocular pain market is expected to witness continued innovation driven by enhanced understanding of disease pathophysiology, improved diagnostic capabilities, and personalized treatment approaches. While significant progress has been made with current therapeutic options, challenges remain in addressing the considerable expenses associated with medications, diagnostic procedures, and potential long-term management options. The absence of swift and dependable diagnostic tools for determining the root causes of acute ocular pain continues to present opportunities for innovation. As research continues and awareness grows, the acute ocular pain market is poised for remarkable expansion and therapeutic innovation through 2034.
Table of Contents
1. Key Insights
2. Executive Summary of Acute Ocular Pain
3. Competitive Intelligence Analysis for Acute Ocular Pain
4. Acute Ocular Pain Market Overview at a Glance
5. Acute Ocular Pain: Disease Background and Overview
6. Acute Ocular Pain Patient Journey
7. Acute Ocular Pain Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Acute Ocular Pain Unmet Needs
10. Key Endpoints of Acute Ocular Pain Treatment
11. Acute Ocular Pain Marketed Products
12. Acute Ocular Pain Emerging Therapies
13. Acute Ocular Pain: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Acute Ocular Pain
17. KOL Views
18. Acute Ocular Pain Market Drivers
19. Acute Ocular Pain Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Related Reports
Acute Ocular Pain and Inflammation Pipeline Insight
Acute Ocular Pain pipeline insight provides comprehensive insights about the Acute Ocular Pain pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Acute Ocular Pain companies, including Ocular Therapeutix, Kala Pharmaceuticals, Sun Pharmaceutical, Bausch & Lomb, Formosa Pharmaceuticals, Aldeyra Therapeutics, and Sylentis, among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services